Adult Dosing

Hyperphosphatemia

• 500 mg PO tid with meals

• Tablets must be chewed and not swallowed. They may be crushed to aid in chewing.
• Monitor serum phosphorus levels and titrate the dose in decrements or increments of 500 mg as needed until an acceptable serum phosphorus level is reached, with regular monitoring afterwards
• Start titration as early as 1 week after treatment initiation and adjust at weekly intervals thereafter if necessary
• Highest daily dose studied in patients with ESRD is 6 tablets or 3,000 mg/day)

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Monitor effect and iron homeostasis with patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal surgery, or with a history of hemochromatosis or other diseases with iron accumulation
• Do not use with vitamin D analogs or levothyroxine

Pregnancy Category:B

Breastfeeding: Safety unknown

• GI: Diarrhea, discolored feces, nausea

• Phosphate binder; phosphate binding takes place by ligand exchange between hydroxyl groups and/or water in sucroferric oxyhydroxide and the phosphate in the diet. The bound phosphate is eliminated with feces, thereby reduces dietary phosphate absorption
• Metabolosm: Unknown
• Excreted in feces
• Half-life: Unknowm

US Trade Name(s)

• Velphoro

US Availability

Velphoro

• CHEW TABS: 500 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Endocrine/Metabolic

Phosphate Binders